Report copyright - Why Brand Volu… · ¾ Cost competitiveness (Ranbaxy-Daiichi) Product) Product portfolio ¾ e.g. Suzlon-RE Power) The acquisition would give Suzlon access to Europe.. Besides, RE
Please pass captcha verification before submit form
Please pass captcha verification before submit form